STAT+: Pharmalittle: Merck ends late-stage trial for Keytruda in prostate cancer; doctor group says 60 Minutes segment on Wegovy was an ad
6 days ago - By STAT
Good morning, everyone, and how are you today? We are doing just fine, thank you, despite the cloudy skies looming over the Pharmalot campus. After all, the birds are still chirping and a tolerable breeze is wafting by. Moreover, this marks the middle of the week, which means we have managed to survive this far. And this calls for celebration, yes? So please join us as we hoist another cup of delicious stimulation. Our choice today is peppermint mocha. Meanwhile, here are a few items of interest. Have a grand day and drop us a line if you hear something saucy....
Merck is discontinuing a...
Read more ...
The headlines of Care Mag
Drink Your Coffee First Thing? Add This To Make It Blood Sugar Friendly
This one addition can make all the difference
STAT+: KKR veteran sets records with $3.9 billion health care fund
The former head of health care investing at private equity giant KKR has set records with the first fundraising for his new firm. The firm, Patient Square Capital, closed on...
How To Ground Yourself When You Feel Uncomfortable In Your Body
A healthy relationship with your body begins by being comfortable with your physicality.
Curing Fish Is Easier Than You Think: An RD's Go-To Recipe
This omega-3-packed only requires a few minutes of prep work.
A Peek Inside An M.D.'s "Biohacker Room" + Her Favorite Tools For Sleep
At the end of the day, you can find Molly Maloof, M.D. on an infrared mat.
Oh, Cool: Tiktok “Invented” Another Very Normal Skin Care Habit
It's actually top notch for thirsty skin.
New Research Reveals The Top 3 Ways To Wake Up Energized Every Morning
Being a "morning person" isn't genetic, after all.
Opinion: Promises - and pitfalls - of ChatGPT-assisted medicine
Not long after the artificial intelligence company OpenAI released its ChatGPT chatbot, the application went viral. Five days after its release, it had garnered 1 million...
STAT+: 6 things to know about Apellis' eye drug ahead of FDA decision
The Food and Drug Administration is nearing a decision on the first treatment for geographic atrophy, a progressive eye disease and a leading cause of blindness in older...
Opinion: Unlocking the promise of learning from everyone with cancer
Locked behind the firewalls of proprietary systems sits a treasure trove of data that could help diagnose heart disease, diabetes, cancer, and other conditions faster and more...